Clinical Trial Update: Study of Controlled Release Formulations of CE-224,535 Against the Immediate Release Formulation in Normal Volunteers [Phase 1]

View source ↗

Summary

Pfizer completed a Phase 1 clinical trial comparing controlled-release CE-224,535 formulations with the immediate-release form in healthy volunteers; rheumatoid…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• CE-224,535

Snippet

Sponsor: Pfizer | Conditions: Rheumatoid Arthritis | Phase 1 | Status: COMPLETED